SCHEMBL1864686

SCHEMBL1864686

CN(c1ccc([N+](=O)[O-])cc1F)C1CCNCC1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.50
MAPT P10636 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
CHRNB4 P30926 2/20 0.39
CHRNA3 P32297 2/20 0.39
CYP19A1 P11511 6/20 0.39
HIF1A Q16665 1/20 0.39
DDB1 Q16531 1/20 0.37
CRBN Q96SW2 1/20 0.37
ADRA2A P08913 1/20 0.37
PNMT P11086 1/20 0.37
KDM4E B2RXH2 1/20 0.37
KMT2A Q03164 1/20 0.36
LMNA P02545 1/20 0.36
SLC6A4 P31645 1/20 0.35
ADRB1 P08588 1/20 0.35
SIRT6 Q8N6T7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27178979 0.80 ALDH1A1 (0.46) ALDH1A1MAPTNPSR1CYP19A1HIF1A
SCHEMBL6118273 0.80 HTT (0.47) ALDH1A1MAPTNPSR1CYP19A1LMNA
SCHEMBL1866831 0.79 ALDH1A1 (0.51) ALDH1A1MAPTNPSR1KDM4EKMT2A
SCHEMBL1866832 0.79 ALDH1A1 (0.51) ALDH1A1MAPTNPSR1KDM4EKMT2A
SCHEMBL15305259 0.79 DDB1 (0.52) DDB1CRBNSLC6A4
SCHEMBL27178860 0.77 MAPT (0.44) ALDH1A1MAPTNPSR1CHRNB4CHRNA3
SCHEMBL13757000 0.77 SLC6A2 (0.40) DDB1CRBNKMT2ASLC6A4
SCHEMBL17155073 0.76 ALDH1A1 (0.46) ALDH1A1MAPTNPSR1CHRNB4CHRNA3
SCHEMBL13718304 0.75 ALDH1A1 (0.58) ALDH1A1MAPTCYP19A1HIF1AKDM4E
SCHEMBL27178780 0.74 ALDH1A1 (0.46) ALDH1A1MAPTNPSR1CYP19A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9108939-B2 (1, 1, 1,3,3,3-hexafluoro-2 hydroxypropan-2-yl) phenyl derivative, pharmaceutical compositions thereof and their use for the treatment of atherosclerosis MERCK SHARP & DOHME B.V. (NL) 2015-08-18 US disclosed
EP-2493855-B1 (1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl derivatives, pharmaceutical compositions thereof and their use for the treatment of atherosclerosis MERCK SHARP & DOHME (NL) 2014-02-26 EP disclosed
US-20120238574-A1 (1, 1, 1,3,3,3 -HEXAFLUORO-2 HYDROXYPROPAN- 2 -YL) PHENYL DERIVATIVE, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS N.V. ORGANON (NL) 2012-09-20 US disclosed
EP-2493855-A1 (1,1, 1,3, 3, 3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL) PHENYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS MSD Oss B.V. (NL) 2012-09-05 EP disclosed
WO-2011051282-A1 (1,1, 1,3, 3, 3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL) PHENYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS N.V. ORGANON (NL) 2011-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238574-A1 (1, 1, 1,3,3,3 -HEXAFLUORO-2 HYDROXYPROPAN- 2 -YL) PHENYL DERIVATIVE, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS TGFB1, FPR1, TGFB2 ALDH1A1 220/4885MAPT 2944/4885NPSR1 2064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.